Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -106.34 Million USD | 5.66% |
| 2021 | -115.39 Million USD | -25.06% |
| 2020 | -91.88 Million USD | -6.4% |
| 2019 | -86.35 Million USD | -48.63% |
| 2018 | -58.1 Million USD | -117.64% |
| 2017 | -26.69 Million USD | -113.06% |
| 2016 | -12.53 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -24.26 Million USD | -17.57% |
| 2023 Q3 | -11.18 Million USD | 35.97% |
| 2023 Q2 | -17.46 Million USD | 28.03% |
| 2022 Q2 | -28.84 Million USD | -2.28% |
| 2022 Q3 | -29.18 Million USD | -1.17% |
| 2022 FY | - USD | 5.66% |
| 2022 Q1 | -28.2 Million USD | -2.38% |
| 2022 Q4 | -20.64 Million USD | 29.27% |
| 2021 Q4 | -27.54 Million USD | 13.82% |
| 2021 Q1 | -26.77 Million USD | 5.05% |
| 2021 Q2 | -26.95 Million USD | -0.66% |
| 2021 FY | - USD | -25.06% |
| 2021 Q3 | -31.96 Million USD | -18.6% |
| 2020 Q3 | -19.72 Million USD | -0.08% |
| 2020 Q2 | -19.7 Million USD | 13.46% |
| 2020 Q4 | -28.19 Million USD | -42.99% |
| 2020 FY | - USD | -6.4% |
| 2020 Q1 | -22.77 Million USD | -0.44% |
| 2019 Q4 | -22.67 Million USD | -7.77% |
| 2019 Q2 | -21.38 Million USD | -2.8% |
| 2019 Q1 | -20.8 Million USD | -30.08% |
| 2019 FY | - USD | -48.63% |
| 2019 Q3 | -21.03 Million USD | 1.65% |
| 2018 Q2 | -14.56 Million USD | -47.98% |
| 2018 FY | - USD | -117.64% |
| 2018 Q4 | -15.99 Million USD | 0.87% |
| 2018 Q3 | -16.13 Million USD | -10.8% |
| 2018 Q1 | -9.84 Million USD | -25.8% |
| 2017 Q1 | -5.04 Million USD | 0.0% |
| 2017 Q2 | -6.03 Million USD | -19.54% |
| 2017 Q3 | -7.79 Million USD | -29.32% |
| 2017 Q4 | -7.82 Million USD | -0.29% |
| 2017 FY | - USD | -113.06% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -23675.297% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -260.418% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 6.759% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -574.735% |
| Better Therapeutics, Inc. | -38.26 Million USD | -177.939% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -177.917% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -494.552% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -215.255% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -218.656% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -11541.833% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -227.397% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -127.759% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -1771.037% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -552.375% |
| Molecular Templates, Inc. | 1.43 Million USD | 7536.713% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -666.445% |
| NexImmune, Inc. | -28.16 Million USD | -277.545% |
| Orgenesis Inc. | -60.71 Million USD | -75.146% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -107.324% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -144752.621% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -558.676% |
| Scopus BioPharma Inc. | -11.71 Million USD | -807.911% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 80.304% |
| Statera Biopharma, Inc. | 38.93 Million USD | 373.135% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -1444.814% |
| Trevena, Inc. | -35.28 Million USD | -201.363% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -189628.997% |
| Vaccinex, Inc. | -19.74 Million USD | -438.51% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -10057.329% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -126.932% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1364.2% |